{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:25:46Z","timestamp":1779110746945,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-021-05024-w","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:03:46Z","timestamp":1635764626000},"page":"1925-1937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1907-0864","authenticated-orcid":false,"given":"Delamo I.","family":"Bekele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reimold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-1485","authenticated-orcid":false,"given":"Christian","family":"Geier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavya","family":"Ganuthula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-0845","authenticated-orcid":false,"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-2376","authenticated-orcid":false,"given":"Daniel O.","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-1515","authenticated-orcid":false,"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0126-1275","authenticated-orcid":false,"given":"Bernard","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3763-6884","authenticated-orcid":false,"given":"Ryan","family":"Duong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jina","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-3235","authenticated-orcid":false,"given":"Gail S.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"5024_CR1","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","volume":"1","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Dougados M, Baeten D (2015) Axial spondyloarthritis. Nat Rev Dis primers 1:15013. https:\/\/doi.org\/10.1038\/nrdp.2015.13","journal-title":"Nat Rev Dis primers"},{"issue":"2","key":"5024_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40744-019-0148-4","volume":"6","author":"T Hunter","year":"2019","unstructured":"Hunter T, Schroeder K, Sandoval D, Deodhar A (2019) Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther 6(2):207\u2013215. https:\/\/doi.org\/10.1007\/s40744-019-0148-4","journal-title":"Rheumatol Ther"},{"issue":"9313","key":"5024_CR3","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/s0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, S\u00f6rensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187\u20131193. https:\/\/doi.org\/10.1016\/s0140-6736(02)08215-6","journal-title":"Lancet"},{"issue":"7","key":"5024_CR4","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146. https:\/\/doi.org\/10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5024_CR5","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230\u20133236. https:\/\/doi.org\/10.1002\/art.11325","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5024_CR6","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402\u20133412. https:\/\/doi.org\/10.1002\/art.23969","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5024_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 73(1):39\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204231","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5024_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70(6):973\u2013981. https:\/\/doi.org\/10.1136\/ard.2010.147744","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5024_CR9","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.141278","volume":"42","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E (2015) Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol 42(8):1418\u20131426. https:\/\/doi.org\/10.3899\/jrheum.141278","journal-title":"J Rheumatol"},{"issue":"10","key":"5024_CR10","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063\u20133070. https:\/\/doi.org\/10.1002\/art.23901","journal-title":"Arthritis Rheum"},{"key":"5024_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, Landew\u00e9 R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R, Canadian (M03-606) study group, and ATLAS study group (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/ar2794","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"5024_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324\u20131331. https:\/\/doi.org\/10.1002\/art.23471","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5024_CR13","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, M\u00e4rker-Hermann E, Zeidler H, Braun J, Sieper J (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort. Ann Rheum Dis 71(10):1616\u20131622. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201252","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5024_CR14","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, van der Heijde D, Landew\u00e9 R, B\u00e9hier JM, Calin A, Olivieri I, Zeidler H, Dougados M (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756\u20131765. https:\/\/doi.org\/10.1002\/art.21054","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5024_CR15","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, Ward MM, Reveille JD, Gensler LS (2013) The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65(10):2645\u20132654. https:\/\/doi.org\/10.1002\/art.38070","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5024_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, R\u00f8devand E, Kaufmann C, Mowinckel P, Kvien TK (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59(2):234\u2013240. https:\/\/doi.org\/10.1002\/art.23333","journal-title":"Arthritis Rheum"},{"issue":"3","key":"5024_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, Yu D (2017) Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 47(3):343\u2013350. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.04.005","journal-title":"Semin Arthritis Rheum"},{"key":"5024_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fmed.2018.00062","volume":"5","author":"A Molt\u00f3","year":"2018","unstructured":"Molt\u00f3 A, Nikiphorou E (2018) Comorbidities in spondyloarthritis. Front Med 5:62. https:\/\/doi.org\/10.3389\/fmed.2018.00062","journal-title":"Front Med"},{"issue":"8","key":"5024_CR19","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/acr.23468","volume":"70","author":"E Nikiphorou","year":"2018","unstructured":"Nikiphorou E, Ramiro S, van der Heijde D, Norton S, Molt\u00f3 A, Dougados M, van den Bosch F, Landew\u00e9 R (2018) Association of comorbidities in spondyloarthritis with poor function, work disability, and quality of life: results from the assessment of spondyloarthritis international society comorbidities in spondyloarthritis study. Arthritis Care Res 70(8):1257\u20131262. https:\/\/doi.org\/10.1002\/acr.23468","journal-title":"Arthritis Care Res"},{"key":"5024_CR20","doi-asserted-by":"crossref","unstructured":"Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, Poddubnyy D (2019). Association of comorbidities with disease activity and functional impairment in axial spondyloarthritis: results from a nationwide population-based study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/association-of-comorbidities-with-disease-activity-and-functional-impairment-in-axial-spondyloarthritis-results-from-a-nationwide-population-based-study\/. Accessed 22 Nov 2019","DOI":"10.1186\/s13075-020-02301-0"},{"issue":"6","key":"5024_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, S\u00f8rensen IJ, Ozgocmen S, Roussou E, Valle-O\u00f1ate R, Sieper J (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783. https:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5024_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2):149\u2013158. https:\/\/doi.org\/10.1016\/S0304-3959(01)00349-9","journal-title":"Pain"},{"issue":"12","key":"5024_CR23","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"12","key":"5024_CR24","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281\u20132285","journal-title":"J Rheumatol"},{"issue":"2","key":"5024_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.rdc.2016.01.011","volume":"42","author":"DT Nhan","year":"2016","unstructured":"Nhan DT, Caplan L (2016) Patient-reported outcomes in axial spondyloarthritis. Rheum Dis Clin North Am 42(2):285\u2013299. https:\/\/doi.org\/10.1016\/j.rdc.2016.01.011","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"5024_CR26","first-page":"851","volume":"33","author":"H Che","year":"2015","unstructured":"Che H, Etcheto A, Dernis E, Nataf H, Boumier P, Breuillard P, Durandin-Truffinet M, Fechtenbaum J, Gaud-Listrat V, Giraud B, Hudry C, Labatide-Alanore S, Le Devic P, Le Goux P, Lebrun A, Maheu E, Moura B, Nguyen M, Sacchi A, Ayral X, Molt\u00f3 A (2015) Evaluation of collected outcome measures in axial spondyloarthritis in daily-care rheumatology settings: the experience of the RHEVER network. Clin Exp Rheumatol 33(6):851\u2013857","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"5024_CR27","first-page":"951","volume":"26","author":"D van der Heijde","year":"1999","unstructured":"van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N (1999) Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS working group. Assessments in ankylosing spondylitis. J Rheumatol 26(4):951\u2013954","journal-title":"J Rheumatol"},{"key":"5024_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landew\u00e9 R, Maksymowych W, van der Heijde D (2009) The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.2008.104018","journal-title":"Ann Rheum Dis"},{"key":"5024_CR29","unstructured":"Stagg V (2006) \u201cCHARLSON: Stata module to calculate Charlson index of comorbidity,\u201d Statistical Software Components S456719, Boston College Department of Economics, revised 13 Sep 2017"},{"key":"5024_CR30","volume-title":"Stata statistical software: release 15","author":"StataCorp","year":"2017","unstructured":"StataCorp (2017) Stata statistical software: release 15. StataCorp LLC, College Station"},{"issue":"1","key":"5024_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","volume":"21","author":"U Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m U, Olofsson T, Wedr\u00e9n S, Qirjazo I, Askling J (2019) Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther 21(1):128. https:\/\/doi.org\/10.1186\/s13075-019-1908-9","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"5024_CR32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.150389","volume":"42","author":"AV Heinonen","year":"2015","unstructured":"Heinonen AV, Aaltonen KJ, Joensuu JT, L\u00e4hteenm\u00e4ki JP, Pertovaara MI, Romu MK, Hirvonen HE, Simil\u00e4 AK, Blom ML, Nordstr\u00f6m DC (2015) Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol 42(12):2339\u20132346. https:\/\/doi.org\/10.3899\/jrheum.150389","journal-title":"J Rheumatol"},{"key":"5024_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Jansen TLTA, Kallenberg CG, Spoorenberg A (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/ar3369","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"5024_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40744-018-0129-z","volume":"5","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, van der Heijde D, Karki C, Liu M, Park Y, Greenberg JD (2018) Tumor necrosis factor inhibitor discontinuation in patients with ankylosing spondylitis: an observational study from the US-based Corona registry. Rheumatol Ther 5(2):537\u2013550. https:\/\/doi.org\/10.1007\/s40744-018-0129-z","journal-title":"Rheumatol Ther"},{"key":"5024_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s13075-015-0897-6","volume":"17","author":"JK Wallman","year":"2015","unstructured":"Wallman JK, Kapetanovic MC, Petersson IF, Geborek P, Kristensen LE (2015) Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients\u2013baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Res Ther 17:378. https:\/\/doi.org\/10.1186\/s13075-015-0897-6","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5024_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3899\/jrheum.160958","volume":"44","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, S\u00f8rensen IJ, \u00d8stergaard M, Dreyer L, Mohamoud AA, Krogh NS, Hendricks O, Andersen LS, Raun JL, Kowalski MR, Danielsen L, Pelck R, Nordin H, Pedersen JK, Kraus DG, Christensen SR, Hansen IM, Esbesen J, Schlemmer A, Loft AG, Hetland ML (2017) Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 status. An observational cohort study from the nationwide DANBIO registry. J Rheumatol 44(1):59\u201369. https:\/\/doi.org\/10.3899\/jrheum.160958","journal-title":"J Rheumatol"},{"issue":"9","key":"5024_CR37","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","volume":"59","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane GJ, Pathan E, Jones GT, Dean LE (2020) Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford) 59(9):2481\u20132490. https:\/\/doi.org\/10.1093\/rheumatology\/kez657","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"5024_CR38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72(7):1149\u20131155. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201933","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5024_CR39","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Caplan L (2019) 2019 Update of the American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol (Hoboken) 71(10):1599\u20131613. https:\/\/doi.org\/10.1002\/art.41042","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"10","key":"5024_CR40","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s10067-017-3767-6","volume":"36","author":"F Jamalyaria","year":"2017","unstructured":"Jamalyaria F, Ward MM, Assassi S, Learch TJ, Lee M, Gensler LS, Brown MA, Diekman L, Tahanan A, Rahbar MH, Weisman MH, Reveille JD (2017) Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol 36(10):2359\u20132364. https:\/\/doi.org\/10.1007\/s10067-017-3767-6","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5024_CR41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3899\/jrheum.181019S","volume":"47","author":"DK Singh","year":"2020","unstructured":"Singh DK, Magrey MN (2020) Racial differences in clinical features and comorbidities in ankylosing spondylitis in the United States. J Rheumatol 47(6):835\u2013838. https:\/\/doi.org\/10.3899\/jrheum.181019S","journal-title":"J Rheumatol"},{"key":"5024_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12891-015-0620-4","volume":"16","author":"M Lorenzin","year":"2015","unstructured":"Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R (2015) Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord 16:166. https:\/\/doi.org\/10.1186\/s12891-015-0620-4","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"5024_CR43","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/acr.23465","volume":"70","author":"M Alazmi","year":"2018","unstructured":"Alazmi M, Sari I, Krishnan B, Inman RD, Haroon N (2018) Profiling response to tumor necrosis factor inhibitor treatment in axial spondyloarthritis. Arthritis Care Res 70(9):1393\u20131399. https:\/\/doi.org\/10.1002\/acr.23465","journal-title":"Arthritis Care Res"},{"issue":"7","key":"5024_CR44","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s10067-018-4086-2","volume":"37","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Song X, Kim G, Park Y (2018) Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol 37(7):1869\u20131878. https:\/\/doi.org\/10.1007\/s10067-018-4086-2","journal-title":"Clin Rheumatol"},{"issue":"9","key":"5024_CR45","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1093\/rheumatology\/keaa900","volume":"60","author":"SS Zhao","year":"2021","unstructured":"Zhao SS, Jones GT, Macfarlane GJ, Hughes DM, Moots RJ, Goodson NJ (2021) Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology (Oxford) 60(9):4158\u20134165. https:\/\/doi.org\/10.1093\/rheumatology\/keaa900","journal-title":"Rheumatology (Oxford)"},{"key":"5024_CR46","doi-asserted-by":"publisher","first-page":"6107217","DOI":"10.1155\/2019\/6107217","volume":"2019","author":"M Biggioggero","year":"2019","unstructured":"Biggioggero M, Mesina F, Favalli EG (2019) The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors. Biomed Res Int 2019:6107217. https:\/\/doi.org\/10.1155\/2019\/6107217","journal-title":"Biomed Res Int"},{"issue":"4","key":"5024_CR47","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40744-020-00248-x","volume":"7","author":"P Karmacharya","year":"2020","unstructured":"Karmacharya P, Shahukhal R, Crowson CS, Murad MH, Davis JM 3rd, Shrestha P, Bekele D, Wright K, Chakradhar R, Dubreuil M (2020) Effects of therapies on cardiovascular events in ankylosing spondylitis: a systematic review and meta-analysis. Rheumatol Ther 7(4):993\u20131009. https:\/\/doi.org\/10.1007\/s40744-020-00248-x","journal-title":"Rheumatol Ther"},{"issue":"4","key":"5024_CR48","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","volume":"166","author":"CS Crowson","year":"2013","unstructured":"Crowson CS, Liao KP, Davis JM 3rd, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, Gabriel SE (2013) Rheumatoid arthritis and cardiovascular disease. Am Heart J 166(4):622-628.e1. https:\/\/doi.org\/10.1016\/j.ahj.2013.07.010","journal-title":"Am Heart J"},{"issue":"3","key":"5024_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/BOR.0b013e32835fd7f8","volume":"25","author":"M Barbhaiya","year":"2013","unstructured":"Barbhaiya M, Solomon DH (2013) Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 25(3):317\u2013324. https:\/\/doi.org\/10.1097\/BOR.0b013e32835fd7f8","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"5024_CR50","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/rheumatology\/","volume":"55","author":"B Glintborg","year":"2016","unstructured":"Glintborg B, H\u00f8jgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, Chrysidis S, Jensen Hansen IM, Holland-Fischer M, H\u00f8jland Hansen T, Nilsson C, Espesen J, Nordin H, Rasmussen Loft AG, Pelck R, Lorenzen T, Flejsborg Oeftiger S, Unger B, Jaeger F, Mosborg Petersen P, Dreyer L (2016) Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford) 55(4):659\u2013668. https:\/\/doi.org\/10.1093\/rheumatology\/","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"5024_CR51","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/acr.23851","volume":"72","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Yoshida K, Jones GT, Hughes DM, Tedeschi SK, Lyu H, Moots RJ, Solomon DH, Goodson NJ (2020) Impact of smoking in response to tumor necrosis factor inhibitors in axial spondyloarthritis: methodologic considerations for longitudinal observational studies. Arthritis Care Res 72(4):591\u2013599. https:\/\/doi.org\/10.1002\/acr.23851","journal-title":"Arthritis Care Res"},{"issue":"4","key":"5024_CR52","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/annrheumdis-2015-208490","volume":"75","author":"L Dreyer","year":"2016","unstructured":"Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H (2016) Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. Ann Rheum Dis 75(4):785\u2013786. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208490","journal-title":"Ann Rheum Dis"},{"key":"5024_CR53","doi-asserted-by":"crossref","unstructured":"Bekele D, Cheng E, Geier C, Ganuthula K, Walsh J, Dubreuil M, Clegg DO, Kaushik P, Ng B, Chang E, Reimold A, Raychaudhuri SP, Duong R, Kuhn KA, Park Y, Kerr GS (2018) Tumor necrosis factor inhibitor persistence and reasons for discontinuation in US veterans with axial spondyloarthritis [abstract]. Arthritis Rheumatol, 70 (suppl 10). https:\/\/acrabstracts.org\/abstract\/tumor-necrosis-factor-inhibitor-persistence-and-reasons-for-discontinuation-in-us-veterans-with-axial-spondyloarthritis\/. Accessed 15 Sept 2021","DOI":"10.1007\/s00296-021-05024-w"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05024-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-05024-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05024-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T15:10:33Z","timestamp":1664205033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-05024-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["5024"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-05024-w","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"16 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The other authors have disclosed no conflicts of interest. Dr. Kerr has received current and prior grant funding from Novartis, BMS and Pfizer. She currently serves on the advisory board for Janssen. Dr. Walsh has received consulting fees from AbbVie, Lilly, Novartis and UCB (all less than $10,000). She has also received research funding from AbbVie and Pfizer. Dr. Clegg has received VA Merit Review funding. Dr. Reimold has served as a consultant for Lilly (less than $10,000).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval obtained by the local Institutional Review Board at each participating site, and by the independent Scientific Ethics and Advisory Committee for the Department of Veterans Affairs (VA) Program to Understand the Longterm Outcomes in SpondyloARthritis registry (PULSAR). Ethics Approval MIRB number: 01138. Initial approval: 08\/28\/2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}